From Yahoo Finance: 2025-05-24 10:59:00

Pfizer Inc. showcases groundbreaking results at the 2025 ASCO Annual Meeting, revealing a 30% reduction in the risk of death with XTANDI plus ADT in metastatic hormone-sensitive prostate cancer. The five-year survival rate jumps to 66%, solidifying XTANDI’s position as a standard of care.

Despite Pfizer Inc.’s oncology advancements, shares only rose 2% due to trade tensions. The company’s total return in the past year is down 14.32%, trailing the pharmaceutical sector. Analysts predict a price target of $29.50, emphasizing the importance of future drug approvals and market expansion for growth.

Pfizer Inc.’s success hinges on strategic collaborations and licensing agreements for competitive leverage and revenue growth. While the potential for growth exists, some analysts believe other AI stocks may offer better returns and less risk. Consider exploring alternative AI stocks for higher upside potential.

Read more: Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost